icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 23-26 2021
Back grey_arrow_rt.gif
 
 
 
Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after Direct-acting Hepatitis C therapeutics corresponds to a lower incidence rate of hepatocellular carcinoma below the cost-effective threshold for surveillance
 
 
  EASL 2021 Presented at The International Liver Congress (EASL), 23-26 June 2021
 
Winston Dunn MD1, Devin Koestler2, Liyun Ni3, Kathryn Kersey3, Bruce Kreter3, Kyle Hammond3, Anand Chokkalingam3, Diana Brainard3, and Steven A Weinman MD PhD FAASLD1 (1)Internal Medicine, University of Kansas Medical Center, Kansas City, USA, (2)Biostatistics, University of Kansas Medical Center, Kansas City, USA,(3)Gilead Sciences, Inc. Foster City, USA

0623211

0623212

0623213

0623214

0623215

0623216

0623217

0623218